BIRC5 and chronic myelogenous leukemia, BCR-ABL1 positive: Therefore, survivin antisense silencing was found to reduce the viability and to increase the efficacy of Imatinib treatment in chronic myeloid leukemia (CML) cell lines, as well as in myeloid progenitors from CML patients39,40.